Author:
Nicoletto M. O.,Tumolo S.,Sorio R.,Cima G.,Endrizzi L.,Nascimben O.,Vinante O.,Artioli G.,Donach M.,Cartei G.
Abstract
The purpose of this study was to compare long-term survival in first-line chemotherapy with and without platinum in advanced-stage ovarian cancer. From July 1987 to November 1992, 161 untreated patients with FIGO stage III–IV epithelial ovarian cancer were randomized: 81 patients received no platinum and 80 received platinum combination. Residual disease after surgery was <2 cm in 61 patients without platinum, 59 with platinum. Median age was 58 years in nonplatinum arm and 55 years in platinum arm (range: 15–73). Complete and partial responses were 51% and 10% for nonplatinum arm and 51% and 8% for platinum arm, respectively (P= 0.7960). Stable disease was observed in 18% of patients in nonplatinum arm and 15% of patients in platinum arm and progression in 20% of nonplatinum- and 21% of platinum-treated cases. Ten-year disease-free survival was 37% for therapy without platinum and 31% for platinum combination (P= 0.5679); 10-year overall survival was 23% without platinum and 31% with platinum combination (P= 0.2545). Fifteen-year overall survival showed a trend of short duration in favor of platinum (P= 0.0678). Relapses occurred after 60 months in ten patients (seven with and three without platinum). The overall and disease-free survivals at 5, 10, and 15 years show no statistically significant long-term advantage from the addition of cisplatin; however, there is a slight trend in its favor.
Subject
Obstetrics and Gynaecology,Oncology
Reference25 articles.
1. Sopravvivenza dei casi di tumore in Italia negli anni novanta: i dati dei registri tumori;Rosso;Epidemiol Prev,2001
2. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results;Griffiths;Int J Gynecol Cancer,2002
3. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma;Wiltshaw;J Clin Oncol,1986
4. Randomized comparison of cisplatin with cyclophosphamide/cisplatin in cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer;Gruppo Interregionale Cooperativo Oncologico Ginecologia (Bolis G, MS, Belloni C et al.);Lancet,1987
5. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study;Muggia;J Clin Oncol,2000
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献